88 related articles for article (PubMed ID: 27383882)
21. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen.
Denmeade SR; Lou W; Lövgren J; Malm J; Lilja H; Isaacs JT
Cancer Res; 1997 Nov; 57(21):4924-30. PubMed ID: 9354459
[TBL] [Abstract][Full Text] [Related]
22. Separation of enzymatically active and inactive prostate-specific antigen (PSA) by peptide affinity chromatography.
Wu P; Stenman UH; Pakkala M; Närvänen A; Leinonen J
Prostate; 2004 Mar; 58(4):345-53. PubMed ID: 14968435
[TBL] [Abstract][Full Text] [Related]
23. KLKs and their hormone-like signaling actions: a new life for the PSA-KLK family.
Hollenberg MD
Biol Chem; 2014 Sep; 395(9):915-29. PubMed ID: 25153380
[TBL] [Abstract][Full Text] [Related]
24. PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility.
Lai J; Kedda MA; Hinze K; Smith RL; Yaxley J; Spurdle AB; Morris CP; Harris J; Clements JA
Carcinogenesis; 2007 May; 28(5):1032-9. PubMed ID: 17151093
[TBL] [Abstract][Full Text] [Related]
25. Tumor biomarkers: PSA and beyond.
Melichar B
Clin Chem Lab Med; 2012 Nov; 50(11):1865-9. PubMed ID: 23072854
[No Abstract] [Full Text] [Related]
26. Antibody immunoglobulin G (IgG) against human prostatic specific antigen (PSA) as a carrier protein for chemotherapeutic drugs to human prostate tumors: Part 1. A double immunofluorescence analysis.
Sinha AA; Sackrison JL; DeLeon OF; Wilson MJ; Gleason DF
Anat Rec; 1996 Aug; 245(4):652-61. PubMed ID: 8837723
[TBL] [Abstract][Full Text] [Related]
27. Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries.
Matsumura M; Bhatt AS; Andress D; Clegg N; Takayama TK; Craik CS; Nelson PS
Prostate; 2005 Jan; 62(1):1-13. PubMed ID: 15389820
[TBL] [Abstract][Full Text] [Related]
28. The presence of prostate-specific antigen-related genes in primates and the expression of recombinant human prostate-specific antigen in a transfected murine cell line.
Karr JF; Kantor JA; Hand PH; Eggensperger DL; Schlom J
Cancer Res; 1995 Jun; 55(11):2455-62. PubMed ID: 7538903
[TBL] [Abstract][Full Text] [Related]
29. Design and synthesis of peptide conjugates of phosphoramide mustard as prodrugs activated by prostate-specific antigen.
Wu X; Hu L
Bioorg Med Chem; 2016 Jun; 24(12):2697-706. PubMed ID: 27156193
[TBL] [Abstract][Full Text] [Related]
30. Strategy for sensitive and specific detection of molecular forms of PSA based on 2DE and kinetic analysis: a step towards diagnosis of prostate cancer.
Kumar V; Hassan MI; Singh AK; Dey S; Singh TP; Yadav S
Clin Chim Acta; 2009 May; 403(1-2):17-22. PubMed ID: 19118539
[TBL] [Abstract][Full Text] [Related]
31. Novel splice variants of prostate-specific antigen and applications in diagnosis of prostate cancer.
Pampalakis G; Scorilas A; Sotiropoulou G
Clin Biochem; 2008 May; 41(7-8):591-7. PubMed ID: 18222179
[TBL] [Abstract][Full Text] [Related]
32. A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans.
Cleutjens KB; van der Korput HA; Ehren-van Eekelen CC; Sikes RA; Fasciana C; Chung LW; Trapman J
Mol Endocrinol; 1997 Aug; 11(9):1256-65. PubMed ID: 9259317
[TBL] [Abstract][Full Text] [Related]
33. Crystal structure of a ternary complex between human prostate-specific antigen, its substrate acyl intermediate and an activating antibody.
Ménez R; Michel S; Muller BH; Bossus M; Ducancel F; Jolivet-Reynaud C; Stura EA
J Mol Biol; 2008 Feb; 376(4):1021-33. PubMed ID: 18187150
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and stereochemical preference of peptide 4-aminocyclophosphamide conjugates as potential prodrugs of phosphoramide mustard for activation by prostate-specific antigen (PSA).
Jiang Y; Dipaola RS; Hu L
Bioorg Med Chem Lett; 2009 May; 19(9):2587-90. PubMed ID: 19345094
[TBL] [Abstract][Full Text] [Related]
35. Selective recognition of enzymatically active prostate-specific antigen (PSA) by anti-PSA monoclonal antibodies.
Michel S; Collomb-Clerc E; Geourjon C; Charrier JP; Passagot J; Courty Y; Deléage G; Jolivet-Reynaud C
J Mol Recognit; 2005; 18(3):225-35. PubMed ID: 15593306
[TBL] [Abstract][Full Text] [Related]
36. Cysteine-rich secretory protein 3 plays a role in prostate cancer cell invasion and affects expression of PSA and ANXA1.
Pathak BR; Breed AA; Apte S; Acharya K; Mahale SD
Mol Cell Biochem; 2016 Jan; 411(1-2):11-21. PubMed ID: 26369530
[TBL] [Abstract][Full Text] [Related]
37. Prostate-specific antigen kinetics as a surrogate endpoint in clinical trials of metastatic castration-resistant prostate cancer: a review.
Colloca G
Cancer Treat Rev; 2012 Dec; 38(8):1020-6. PubMed ID: 22503300
[TBL] [Abstract][Full Text] [Related]
38. ["Prostatic" kallikreins, sex hormones and insulin-like growth factors: complex of male and female regulatory elements in health and carcinogenesis].
Zezerov EG; Severin ES
Vestn Ross Akad Med Nauk; 1999; (3):49-56. PubMed ID: 10222833
[TBL] [Abstract][Full Text] [Related]
39. From pro-prostate specific antigen, [-2]pro-prostate specific antigen to Beckman Coulter phi: the evolution of new biomarkers for early detection of prostatic carcinoma.
Zhang MZ; Lu YP
Chin Med J (Engl); 2012 May; 125(9):1643-9. PubMed ID: 22800836
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP).
Graeser R; Chung DE; Esser N; Moor S; Schächtele C; Unger C; Kratz F
Int J Cancer; 2008 Mar; 122(5):1145-54. PubMed ID: 17973264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
